A Comparative Study of the Prescription of Memantine and Piracetam in Poststroke Aphasia

Document Type : Original Article (s)

Authors

1 Associate Professor, Isfahan Neuroscience Research Center AND Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Isfahan Neuroscience Research Center AND Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Student of Medicine, School of Medicine AND Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

4 Student of Medicine, Isfahan Neurosciences Research Center AND Department of Neurology, School of Medicine AND Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Aphasia is an acquired linguistic disease caused by brain injuries mostly in the left hemisphere. The symptoms can contain a vast spectrum of clinical manifestations.Methods: This double-blind randomized clinical trial study observed 70 patients with stroke. Patients’ characteristics and their demographic information registered prior to the intervention. Then, they were divided in two equal groups randomly; one group received piracetam and the other got memantine.Findings: The mean age was 61.6 ± 11.8 and 62.7 ± 11.8 years in memantine and piracetam groups, respectively. Covariance analysis demonstrated more significant improvements in memantine group in all aspects of the study except the fluency of speech.Conclusion: While memantine improve lots of symptoms of aphasia, todays it is less considered by physicians. However, we recommend its prescription in patients with aphasia as a safe and efficient drug.

Keywords

References

  1. El Hachioui H, Sandt-Koenderman MW, Dippel DW, Koudstaal PJ, Visch-Brink EG. The ScreeLing: occurrence of linguistic deficits in acute aphasia post-stroke. J Rehabil Med 2012; 44(5): 429-35.
  2. Berthier ML, Pulvermuller F, Davila G, Casares NG, Gutierrez A. Drug therapy of post-stroke aphasia: a review of current evidence. Neuropsychol Rev 2011; 21(3): 302-17.
  3. Nilipour R, Pourshahbaz A, Ghoreyshi ZS. Reliability and validity of bedside version of Persian WAB (P-WAB-1). Basic Clin Neurosci 2014; 5(4): 253-8.
  4. Navarro SA, Serafim KG, Mizokami SS, Hohmann MS, Casagrande R, Verri WA, Jr. Analgesic activity of piracetam: effect on cytokine production and oxidative stress. Pharmacol Biochem Behav 2013; 105: 183-92.
  5. Gungor L, Terzi M, Onar MK. Does long term use of piracetam improve speech disturbances due to ischemic cerebrovascular diseases? Brain Lang 2011; 117(1): 23-7.
  6. Lam S, Smith C, Gomolin IH. Memantine standard tablet and extended-release dosing considerations: a pharmacokinetic analysis. J Am Geriatr Soc 2015; 63(2): 383-4.
  7. Barbancho MA, Berthier ML, Navas-Sanchez P, Davila G, Green-Heredia C, Garcia-Alberca JM, et al. Bilateral brain reorganization with memantine and constraint-induced aphasia therapy in chronic post-stroke aphasia: An ERP study. Brain Lang 2015; 145-146: 1-10.
  8. Stinton C, McKeith I, Taylor JP, Lafortune L, Mioshi E, Mak E, et al. Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. Am J Psychiatry 2015; 172(8): 731-42.
Journal of Isfahan Medical School
Volume 33, Issue 355 - Serial Number 355
September and October 2015
Pages 1752-1757

Files

History

  • Receive Date: 16 August 2015
  • Revise Date:
  • Accept Date: 06 April 2022

Share

How to cite

Statistics